Ginkgo Bioworks (DNA) Expected to Announce Earnings on Thursday

Ginkgo Bioworks (NYSE:DNA) is projected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Ginkgo Bioworks to announce earnings of ($0.58) per share and revenue of $21.50 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Ginkgo Bioworks (NYSE:DNA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.15. Ginkgo Bioworks had a negative net margin of 259.96% and a negative return on equity of 60.27%. The company had revenue of $20.16 million for the quarter, compared to analysts’ expectations of $24.05 million. On average, analysts expect Ginkgo Bioworks to post ($3.20) EPS for the current fiscal year and ($2.90) EPS for the next fiscal year.

Ginkgo Bioworks Trading Down 12.1%

Ginkgo Bioworks stock opened at $9.85 on Tuesday. Ginkgo Bioworks has a 12 month low of $5.37 and a 12 month high of $18.22. The business’s 50 day simple moving average is $9.60 and its 200 day simple moving average is $8.59. The company has a market cap of $663.16 million, a price-to-earnings ratio of -1.97 and a beta of 1.79.

Analyst Ratings Changes

DNA has been the topic of several research reports. BTIG Research restated a “sell” rating and issued a $5.00 target price on shares of Ginkgo Bioworks in a research note on Friday, September 4th. TD Cowen increased their price target on Ginkgo Bioworks from $9.00 to $11.00 and gave the stock a “hold” rating in a research note on Tuesday, October 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ginkgo Bioworks in a report on Thursday, October 15th. Oppenheimer set a $5.00 price objective on Ginkgo Bioworks in a research note on Wednesday, September 9th. Finally, Wall Street Zen raised shares of Ginkgo Bioworks from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. Two investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $7.00.

Insider Buying and Selling

In related news, insider Steven Coen sold 2,403 shares of Ginkgo Bioworks stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $15.00, for a total value of $36,045.00. Following the completion of the transaction, the insider directly owned 49,448 shares in the company, valued at approximately $741,720. The trade was a 4.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christian Henry sold 5,000 shares of Ginkgo Bioworks stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $7.08, for a total transaction of $35,400.00. Following the completion of the transaction, the director owned 19,310 shares of the company’s stock, valued at $136,714.80. This represents a 20.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 136,525 shares of company stock worth $1,379,699 in the last 90 days. 12.69% of the stock is currently owned by company insiders.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks is a biotechnology company that develops and deploys biological systems for commercial and industrial applications. Its platform is designed to help customers program cells to produce a wide range of products, including pharmaceuticals, food ingredients, agricultural inputs, specialty chemicals and materials. The company combines biological engineering, automation, software and data science to design, build and test engineered organisms.

Ginkgo provides services through its cell-programming platform and biological engineering foundry, supporting activities such as genetic design, strain construction, laboratory testing and process development.